Evotec, Plectonic Launch Research Collaboration on New T-Cell Approaches for Solid Tumors
MT Newswires Live
4 hours ago
Evotec (EVO) and Plectonic Biotech have entered a research collaboration to develop next-generation T-cell-engaging immunotherapies for solid tumors, the companies said Wednesday.
The partnership will combine Evotec's BiTco platform with Plectonic's Logibody technology to address challenges that have limited traditional T-cell engagers in solid tumors, they said.
Under the deal, the companies will generate preclinical proof-of-concept data to assess the potential of these T-cell engaging approaches, they added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.